<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749866</url>
  </required_header>
  <id_info>
    <org_study_id>CZB/4/451</org_study_id>
    <nct_id>NCT00749866</nct_id>
  </id_info>
  <brief_title>Long Term Nebulised Gentamicin in Patients With Bronchiectasis</brief_title>
  <official_title>Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this randomized placebo controlled trial is that targeted nebulized
      gentamicin to the airways will reduce bacterial burden and limit neutrophil airways
      inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise
      capacity and health related quality of life with a reduction in exacerbation frequency and
      health care utilization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in bacterial load</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>airways and systemic inflammation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry and exercise capacity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation frequency</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term safety with nebulised Gentamicin</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebulised Gentamicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nebulised 0.9% Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin</intervention_name>
    <description>Nebulised 80mg twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Nebulised 4mls 0.9% Saline twice daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bronchiectasis confirmed by HRCT of the chest

          -  Clinically stable (not requiring antibiotics for at least 4 weeks preceding the study
             start date)

          -  Aged 18-70

          -  Chronic sputum production &gt; 5 mls for the majority of days in 3 months before
             enrolment

          -  Chronically colonized (on at least 2 occasions in the preceding 12 months) whilst
             clinically stable

          -  At least two exacerbations in the past year

          -  Patients able to tolerate a nebulized gentamicin challenge

          -  FEV1 &gt; 30% predicted

          -  Smoking &lt; 20 pack year history and ex-smokers &gt;1 year.

        Exclusion Criteria:

          -  Cystic fibrosis

          -  Emphysema on HRCT chest

          -  Thoracic surgery within the past 1 year

          -  Allergic bronchopulmonary aspergillosis

          -  Poorly controlled asthma ( &gt; 20% diurnal variation in peak expiratory flows despite
             treatment)

          -  Unstable angina or uncontrolled congestive cardiac failure

          -  Active malignancy

          -  Pregnancy or breast feeding

          -  Creatinine clearance &lt; 30 mls/minute

          -  Vestibular instability

          -  Previous documented intolerance to aminoglycosides
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam T Hill, MBChB MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Lothian and University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>August 9, 2010</last_update_submitted>
  <last_update_submitted_qc>August 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Adam Hill; Consultant Physician and Honorary Senior Lecturer</name_title>
    <organization>NHS Lothian and University of Edinburgh</organization>
  </responsible_party>
  <keyword>Nebulised antibiotics</keyword>
  <keyword>Non cystic fibrosis bronchiectasis</keyword>
  <keyword>Bacterial Load</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Side Effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

